Thalamic Bistable Opsin Targeting for Drug-Resistant Epilepsy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional treatments for epilepsy, such as antiepileptic drugs, surgical interventions, and deep-brain stimulation, have limitations in efficacy, invasiveness, and adverse effects, while optogenetic approaches using light-sensitive proteins have not been effectively applied to treat epilepsy.
Innovation Solution
Administering a polynucleotide encoding a bistable type II opsin, attached to a heterologous ER export and membrane trafficking signal, into the thalamus nucleus, followed by exposing the neural region to activating light to modulate neuronal activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (antiepileptic drugs, surgical interventions, deep-brain stimulation) are used, then epilepsy can be treated to some extent, but they have limitations in efficacy, invasiveness, and adverse effects
Solution Approach 1:
The patent replaces conventional mechanical/surgical interventions (DBS electrodes, surgical resection) with an optical system. Light-sensitive proteins (opsins) are expressed in thalamic neurons, and light delivery through optical fibers enables non-invasive modulation of neuronal activity to prevent seizures, eliminating the need for invasive surgical procedures while maintaining therapeutic efficacy
Solution Approach 2:
The patent changes the fundamental mechanism of action from chemical (antiepileptic drugs) or electrical (DBS) to optical stimulation. By using light wavelengths that activate specific opsins (e.g., channelrhodopsin-2 activated by blue light), the system achieves precise control over neuronal excitability in the thalamus, providing a new parameter dimension for epilepsy treatment that avoids the adverse effects of conventional approaches
2Reliability
If deep-brain stimulation is used, then epilepsy treatment is achieved, but it causes non-specific stimulation leading to adverse effects
Solution Approach 1:
The patent achieves local specificity by targeting light-sensitive proteins expressed in particular thalamic neuron populations. The optical fiber delivers light to a precise anatomical location (thalamus), and the light wavelength is selected to activate specific opsin subtypes, enabling selective modulation of defined neuronal circuits without the diffuse, non-specific stimulation caused by DBS electrodes
Solution Approach 2:
The patent introduces light-sensitive proteins (opsins) as an intermediary between the external light source and the target neurons. These opsins act as wavelength-specific gates that translate optical energy into controlled neuronal activity changes, providing precise spatial and spectral selectivity that avoids the non-specific effects of direct electrical stimulation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively treats epilepsy by inhibiting or preventing seizures, particularly in drug-resistant forms, with reduced invasiveness and adverse effects.
Implementation Method 1
exposing a neural region of the subject to light in a wavelength that activates the bistable type II opsin
Data Source
AI summary
Methods of treating epilepsy are provided. Accordingly, there is provided a method of treating epilepsy in a subject in need thereof, the method comprising: (a) administering into a thalamus nucleus of the subject a therapeutically effective amount of a polynucleotide encoding a bistable type II opsin attached to a heterologous ER export signal and/or membrane trafficking signal which enables trafficking of said bistable type II opsin to axonal presynaptic terminals; and (b) exposing a neural region of said subject to light in a wavelength that activates said bistable type II opsin, wherein said neural region comprises a cell body and/or an axon of said thalamus nucleus.